替尔泊肽：用于治疗 2 型糖尿病的新一代治疗药物。
Tirzepatide: A New Generation Therapeutic for Diabetes Type 2.
机构信息
Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans LA 70125, United States of America.
出版信息
Endocr Metab Immune Disord Drug Targets. 2023;23(8):1046-1050. doi: 10.2174/1871530322666221004151212.
Abstract
Tirzepatide (mounjaro) is a derivative of the human glucose-dependent insulinotropic polypeptide (GIP) hormone with a position-20 being modified with 1,20- eicosanedioic acid via a chemical linker. It acts as a glucagon-like peptide-1 (GLP-1) receptor and GIP receptor agonist. It has recently been approved by FDA as an adjunct therapy to exercise and diet to improve glycemic control in patients with type II diabetes mellitus (T2DM). It represents a new transforming paradigm in the management of T2DM. This mini-review will shed light on its different pharmacokinetic and pharmacodynamic aspects.
摘要
替尔泊肽（度拉糖肽）是一种人源葡萄糖依赖性胰岛素多肽（GIP）激素的衍生物，其 20 位通过化学连接子与 1,20-二十烷二酸连接。它作为胰高血糖素样肽-1（GLP-1）受体和 GIP 受体激动剂。它最近已被 FDA 批准为辅助疗法，与运动和饮食结合使用，以改善 2 型糖尿病（T2DM）患者的血糖控制。它代表了 T2DM 管理的一种新的变革模式。这篇迷你综述将探讨其不同的药代动力学和药效动力学方面。
相似文献
1
Tirzepatide: A New Generation Therapeutic for Diabetes Type 2.替尔泊肽：用于治疗 2 型糖尿病的新一代治疗药物。
Endocr Metab Immune Disord Drug Targets. 2023;23(8):1046-1050. doi: 10.2174/1871530322666221004151212.
2
Tirzepatide: A Review in Type 2 Diabetes.替尔泊肽：用于 2 型糖尿病的治疗。
Drugs. 2024 Feb;84(2):227-238. doi: 10.1007/s40265-023-01992-4. Epub 2024 Feb 23.
3
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.双重葡萄糖依赖性胰岛素促胰岛素多肽（GIP）和胰高血糖素样肽-1（GLP-1）受体激动剂替西帕肽：一种新的代谢治疗前景。
Cardiovasc Diabetol. 2021 Nov 24;20(1):225. doi: 10.1186/s12933-021-01412-5.
4
Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis.与治疗 2 型糖尿病的 GLP-1 或双重 GIP/GLP-1 受体激动剂替西帕肽相关的主要不良心血管事件和中风风险：系统评价和荟萃分析。
Eur Stroke J. 2024 Sep;9(3):530-539. doi: 10.1177/23969873241234238. Epub 2024 Feb 23.
5
Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.替尔泊肽：一种葡萄糖依赖性胰岛素促泌多肽（GIP）和胰高血糖素样肽-1（GLP-1）双重激动剂，正在开发用于治疗 2 型糖尿病。
Expert Rev Endocrinol Metab. 2020 Nov;15(6):379-394. doi: 10.1080/17446651.2020.1830759. Epub 2020 Oct 8.
6
Table: GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes.表：用于2型糖尿病的胰高血糖素样肽-1及胃抑肽/胰高血糖素样肽-1受体激动剂
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-e3. doi: 10.58347/tml.2024.1708c.
7
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.LY3298176，一种新型双重 GIP 和 GLP-1 受体激动剂，用于治疗 2 型糖尿病：从发现到临床概念验证。
Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3.
8
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.双重 GIP 和 GLP-1 受体激动剂替西帕肽可改善 2 型糖尿病患者的β细胞功能和胰岛素敏感性。
J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396. doi: 10.1210/clinem/dgaa863.
9
How May GIP Enhance the Therapeutic Efficacy of GLP-1?GIP 如何增强 GLP-1 的治疗效果？
Trends Endocrinol Metab. 2020 Jun;31(6):410-421. doi: 10.1016/j.tem.2020.02.006. Epub 2020 Mar 16.
10
Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes.替尔泊肽——一种双重 GIP/GLP-1 受体激动剂——一种具有潜在代谢活性的新型抗糖尿病药物，可用于治疗 2 型糖尿病。
Endokrynol Pol. 2022;73(4):745-755. doi: 10.5603/EP.a2022.0029. Epub 2022 May 20.
引用本文的文献
1
A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.已批准的胰高血糖素样肽-1（GLP-1）受体激动剂和双GLP-1/葡萄糖依赖性促胰岛素多肽（GIP）受体激动剂的药代动力学及药物相互作用综述
Drug Des Devel Ther. 2025 Apr 30;19:3509-3537. doi: 10.2147/DDDT.S506957. eCollection 2025.
2
Potential New Treatments for Chronic Kidney Diseases: A Concise Review.慢性肾脏病的潜在新疗法：简要综述
Curr Pharm Des. 2025 Feb 6. doi: 10.2174/0113816128360091250117040009.
3
Genetically predicted metabolites mediate the association between immune cells and metabolic dysfunction-associated steatotic liver disease: a mendelian randomization study.遗传预测代谢物介导免疫细胞与代谢功能障碍相关脂肪性肝病的关联：一项孟德尔随机研究。
Lipids Health Dis. 2024 Aug 16;23(1):249. doi: 10.1186/s12944-024-02245-3.
4
Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity.未来更加光明：治疗糖尿病和肥胖症的新型潜在范式转变药物与治疗方案
Curr Diabetes Rev. 2024;20(8):84-97. doi: 10.2174/0115733998276832231124170324.
5
The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta-regression analysis of randomized controlled trials.皮下注射 Tirzepatide 对肥胖和超重的影响：随机对照试验的系统评价和荟萃回归分析。
Front Endocrinol (Lausanne). 2023 Aug 9;14:1230206. doi: 10.3389/fendo.2023.1230206. eCollection 2023.
本文引用的文献
1
Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis.利拉鲁肽 3.0mg 治疗超重和肥胖伴或不伴糖尿病患者的疗效和安全性：系统评价和荟萃分析。
Int J Clin Pract. 2022 Jul 19;2022:1201977. doi: 10.1155/2022/1201977. eCollection 2022.
2
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.口服肽的新纪元：SNAC 与口服司美格鲁肽治疗 2 型糖尿病的研发。
Rev Endocr Metab Disord. 2022 Oct;23(5):979-994. doi: 10.1007/s11154-022-09735-8. Epub 2022 Jul 15.
3
Tirzepatide: First Approval.替尔泊肽：首次获批
Drugs. 2022 Jul;82(11):1213-1220. doi: 10.1007/s40265-022-01746-8.
4
Exenatide Once Weekly for Management of Type 2 Diabetes: A Review.每周一次艾塞那肽用于2型糖尿病管理：综述
Clin Pharmacol. 2022 Feb 21;14:19-26. doi: 10.2147/CPAA.S288846. eCollection 2022.
5
Wegovy (semaglutide): a new weight loss drug for chronic weight management.韦格利（司美格鲁肽）：一种用于慢性体重管理的新型减肥药。
J Investig Med. 2022 Jan;70(1):5-13. doi: 10.1136/jim-2021-001952. Epub 2021 Oct 27.
6
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.替尔泊肽（双重GIP和GLP-1受体激动剂）在2型糖尿病管理中的作用：SURPASS临床试验
Diabetes Ther. 2021 Jan;12(1):143-157. doi: 10.1007/s13300-020-00981-0. Epub 2020 Dec 15.
7
Introduction: .引言：.
Diabetes Care. 2021 Jan;44(Suppl 1):S1-S2. doi: 10.2337/dc21-Sint.
8
Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.度拉糖肽每周一次给药用于2型糖尿病合并2/3期慢性肾脏病患者的安全性和有效性
Diabetes Ther. 2020 Jul;11(7):1467-1480. doi: 10.1007/s13300-020-00815-z. Epub 2020 Apr 18.
9
Dulaglutide: A Review in Type 2 Diabetes.度拉糖肽：用于 2 型糖尿病的治疗。
Drugs. 2020 Feb;80(2):197-208. doi: 10.1007/s40265-020-01260-9.
10
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.根据 EXSCEL 试验结果，接受每周一次艾塞那肽治疗的患者的微血管和心血管结局与肾功能有关。
Diabetes Care. 2020 Feb;43(2):446-452. doi: 10.2337/dc19-1065. Epub 2019 Nov 22.
Zotero 插件